Intestinal absorption of levodopa in man

Area of Science:

• Pharmacology
• Gastroenterology
• Drug Metabolism

Background:

• Levodopa (l-dopa) is a primary treatment for Parkinson's disease.
• Understanding l-dopa's intestinal absorption is critical for optimizing its therapeutic efficacy.
• Presystemic clearance can significantly impact l-dopa bioavailability.

Purpose of the Study:

• To investigate the intestinal absorption of levodopa (l-dopa) at different sites in the small intestine.
• To determine if the absorption rate and extent of l-dopa vary between the duodenum and jejunum.
• To assess the impact of peripheral decarboxylase inhibition on l-dopa absorption.

Main Methods:

• Four healthy subjects participated in the study.
• Levodopa (l-dopa) was administered at three distinct upper small intestinal sites (proximal duodenum, distal duodenum, upper jejunum).
• Subjects received benserazide pretreatment to inhibit peripheral decarboxylase and minimize presystemic clearance.

Main Results:

• No significant differences in the time to reach maximum plasma concentration (tmax), maximum plasma concentration (cmax), or area under the curve (AUC) of l-dopa were observed.
• Absorption characteristics of l-dopa remained consistent regardless of administration site in the upper small intestine.
• Peripheral decarboxylase inhibition by benserazide appeared effective in standardizing absorption conditions.

Conclusions:

• Intestinal absorption of levodopa (l-dopa) is uniform across the proximal duodenum, distal duodenum, and upper jejunum in healthy individuals.
• Inhibition of peripheral decarboxylase by benserazide ensures consistent l-dopa absorption, irrespective of the administration site in the upper small intestine.
• These findings support the potential for predictable l-dopa pharmacokinetics when administered in the upper gastrointestinal tract under specific conditions.